Form 4: Intellia Therapeutics VP, Chief Accounting Officer Michael P. Dube Reports Acquisition of 14,000 Shares

Michael P. Dube, VP, Chief Accounting Officer of Intellia Therapeutics, reports acquiring 14,000 shares of common stock on March 1, 2025.

Summary

• On March 1, 2025, Michael P. Dube, VP, Chief Accounting Officer of Intellia Therapeutics, acquired 14,000 shares of common stock.
• The shares were acquired at a price of $0.
• Following the transaction, Dube directly owns 59,640 shares of Intellia Therapeutics.
• The acquisition was in the form of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a stock transaction by an officer. The acquisition itself could be seen as mildly positive, but the filing is primarily informational.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company officer.

Key Dates